tradingkey.logo
tradingkey.logo
Search

Z Squared Ord Shs

ZSQR
Add to Watchlist
2.375USD
-0.095-3.85%
Close 11-13 16:00(ET)
125.88MMarket Cap
LossP/E TTM

About Z Squared Ord Shs Company

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology company. The Company is focused on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its segments are Biotechnology and Technology. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed by the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and robotic process automation capabilities. The Company’s subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Z Squared Ord Shs Profile

Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -

Company Executives of Z Squared Ord Shs

Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
330.19K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
70.53K
-7.09%
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
64.03K
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
26.61K
+15.45%
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
26.61K
+15.45%
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
26.61K
+15.45%
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
8.95K
--
Ms. Elissa Stall
Ms. Elissa Stall
Corporate Secretary
Corporate Secretary
--
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Kenneth Cooper
Mr. Kenneth Cooper
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
330.19K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
70.53K
-7.09%
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
64.03K
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
26.61K
+15.45%
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
26.61K
+15.45%
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
26.61K
+15.45%

FAQs

Who are the top five shareholders of Z Squared Ord Shs?

The top five shareholders of Z Squared Ord Shs are: Mr. David Mehalick

How many institutions hold shares of Z Squared Ord Shs (ZSQR)?

As of 2026Q2, 33 institutions hold shares of Z Squared Ord Shs, with a combined market value of approximately 559.94K, accounting for 9.00% of the total shares. Compared to 2026Q1, institutional shareholding has increased by 342900.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.